LG186: An inhibitor of GBF1 function that causes Golgi disassembly in human and canine cells.
Traffic. 2010 Dec; 11(12):1537-51
This article PDF usually requires a subscription to access but you can receive the PDF, at no cost, through a special arrangement between Springer Science+Business Media and Faculty of 1000 for our Faculty Members who act as reviewers. This PDF is provided to you only for the purposes of reviewing the article while you consider preparing a recommendation of the article for F1000Prime. Other than for this purpose you warrant that you will treat the PDF as confidential. Furthermore you warrant that you will not use the PDF for any other purpose, especially but not limited to forwarding, copying, selling, distributing it whether commercially or non-commercially and that you will not make it available on any website for any other purpose.
This article reports the development and characterization of an inhibitor (LG186) of Arf-GEF function that is more selective for GBF1. LG186 induces disassembly of the Golgi without affecting endosomes in both human and canine cells. LG186 may, therefore, be a very useful small molecule inhibitor for trafficking studies involving Golgi and the secretory pathway.
Brefeldin A has been a useful chemical to study the secretory pathway as it causes many cellular changes, including very rapid tubulation of early endosomes, redistribution of endosomes and the trans-Golgi network, and fusion of these two compartments. Such widespread effects are due to inhibition of several GEFs, among them GBF1, BIG1, and BIG2. Golgicide A is a more specific inhibitor of GBF1 but appears to have a binding site that overlaps with brefeldin A. Both brefeldin A and Golgicide A are ineffective against canine GBF1 due to a single amino acid substitution within the binding domain.
The authors of this study used a model of the GBF1 Sec7 domain with docked existing inhibitors to design a new compound, LG186, with improved specificity for GBF1 over BIG1 and BIG2. The design strategy involved targeting a GBF1 tripeptide insertion that is not present in BIG1 and BIG2 but conserved between human and canine sequences. LG186 inhibition of GBF1 causes redistribution of Golgi, does not cause tubulation or enlargement of recycling or early endosomes (in agreement with no inhibition of BIG2), and does not affect localization of AP1 clathrin adaptor (as seen with brefeldin A). Due to increased specificity for both human and canine GBF1, LG186 may be a useful tool for a variety of trafficking experiments.
Some caveats are (1) complete washout and reversibility of LG186 is possible but more variable than brefeldin A and (2) LG186 is less soluble and slower-acting than Golgicide A.
Jan L and Thayer D: F1000Prime Recommendation of [Boal F et al., Traffic 2010, 11(12):1537-51]. In F1000Prime, 09 Dec 2010; DOI: 10.3410/f.6822959.6992057. F1000Prime.com/6822959#eval6992057
F1000Prime Recommendations, Dissents and Comments for [Boal F et al., Traffic 2010, 11(12):1537-51]. In F1000Prime, 18 Apr 2014; F1000Prime.com/6822959
Get the most out of F1000Prime - attend a live online demonstration.
Please choose one of the following time zones:
Want to become an
has been added to your "Faculty I'm Following" page in MyF1000
Follow/Unfollow any Faculty via their recommendations, biography pages, or MyF1000
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
We have sent an email to , please follow the instructions to reset your password.
If you don't receive this email, please check your spam filters and/or contact firstname.lastname@example.org.